SRI and cancer: The analysis showed that sorcin is significantly overexpressed in 25 types of cancer (it is also downregulated in 3 cancers; no significant difference is reported for 5 cancers), and that sorcin expression dysregulation could predict worse prognosis in the patients with many types of cancer.